首页> 外文OA文献 >VP164 Applying health technology assessment to pharmacy: the Italian-Medicine-Use-Review-Health Technology Assessment
【2h】

VP164 Applying health technology assessment to pharmacy: the Italian-Medicine-Use-Review-Health Technology Assessment

机译:Vp164将健康技术评估应用于药房:意大利 - 医学 - 使用 - 评论 - 健康技术评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

There is a lack of Health-Technology-Assessment (HTA) tools in pharmacy practice and the collection of real-world-evidence (RWE) in community pharmacy to populate longer-term-disease-progression-modelling (1). This project is looking at the development and application of a novel Patient-Reported-Outcome- Measure (PROM) in community pharmacy that can enable: the evaluation of the quality of care delivered from the patient perspective in terms of economic impact, patient health outcomes and ‘utilities’; the collection of RWE and evaluate long-term effect of care; to provide different stakeholders with unique evidence-based information that help formulate health policies in community pharmacy that are safe, effective, patient-focused and cost-effective, balancing access to innovation and cost containment.\udEvidence from the Italian-Medicine-Use-Review (I-MUR) trial (2) showed that the I-MUR intervention provided by community pharmacists to asthma patients is effective, cost-saving and cost-effective (3). The trial allowed to model a framework (I-MUR-HTA) that would enable to routinely deliver the intervention, but also collect and analyse PROM data on its clinical-effectiveness, quality-of-life and cost-effectiveness. I-MUR-HTA was discussed within three expert-panel discussions including policy-makers, commissioners, academics, healthcare-professionals and patient-representatives in Italy, United Kingdom and Europe. Current plan include testing the use of the tool in the real world environment.\udEvidence collected from the panel discussions confirmed that I-MUR-HTA evidence-based information is relevant to meet current National-Health-Care-System plans and this is what is needed to support the evaluation of innovative effective and cost-effective health policies and promote their implementation across nations. Current Italian law on pharmacy services provides the appropriate institutional framework to regulate the introduction of I-MUR-HTA across the territory. Its implementation is underway and a real-world pilot is planned to take place in Italy.\udI-MUR-HTA appears to be an innovative tool to promote active patient involvement into policy-decision-making and pharmacy-service.
机译:在药房实践中缺乏健康技术评估(HTA)工具,在社区药房中缺乏现实证据(RWE)来填充长期疾病进展模型(1)。该项目着眼于社区药房中新型患者报告结果测量(PROM)的开发和应用,该方法可实现:从患者角度评估所提供的护理质量,包括经济影响,患者健康状况和“公用事业”;收集RWE并评估护理的长期效果;为不同的利益相关者提供基于证据的独特信息,帮助他们在社区药房中制定安全,有效,以患者为中心且具有成本效益的卫生政策,在创新和成本控制之间取得平衡。回顾(I-MUR)试验(2)显示,社区药师为哮喘患者提供的I-MUR干预是有效,节省成本和成本效益的(3)。该试验允许对框架(I-MUR-HTA)进行建模,该框架将能够例行提供干预措施,而且还可以收集和分析有关其临床效果,生活质量和成本效果的PROM数据。在三个专家小组讨论中对I-MUR-HTA进行了讨论,包括意大利,英国和欧洲的政策制定者,委员,学者,医疗保健专业人员和患者代表。目前的计划包括测试该工具在现实世界环境中的使用。\ ud从小组讨论中收集的证据证实,I-MUR-HTA循证信息与满足当前的国家卫生保健系统计划相关,这就是事实。需要支持对创新有效和具有成本效益的卫生政策进行评估,并促进在全国范围内实施这些政策。意大利现行的药品服务法提供了适当的体制框架,以规范I-MUR-HTA在整个地区的引入。它的实施正在进行中,并计划在意大利进行实际试验。\ udI-MUR-HTA似乎是一种创新工具,可促进患者积极参与决策和药房服务。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号